Vermilion Therapeutics aims to create innovative new drugs from
Japanese science, and aims to innovate new modality and technology
in collaboration with academia science.
Jul. 19, 2022
Research team from Vermilion Therapeutics Inc. and University of Tokyo, has joined Award-Reception of “Cutting-Edge technology” Award
Jun. 09, 2022
Vermilion Therapeutics Inc., University of Tokyo, and Wakayama Medical Univ. has received the “Special Award of Cutting-Edge Technology”
May. 31, 2022
New Review Article for “Photocatalyst as new therapeutic strategy” has been accepted
Vermilion Therapeutics Inc. is aiming to research and develop new treatments for Alzheimer’s disease, Cardiac and Kidney Amyloidosis, Corona virus infections (SARS-CoV-2), and Solid tumors and malignant cancer.